Valuation: Norda ASA

Market Cap 51Cr 5.39Cr 4.81Cr 4.49Cr 4.07Cr 7.66Cr 511.6Cr 7.72Cr 54Cr 21Cr 266.07Cr 20Cr 20Cr 853.8Cr P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 26Cr 2.78Cr 2.48Cr 2.31Cr 2.1Cr 3.94Cr 263.54Cr 3.98Cr 28Cr 11Cr 137.06Cr 10Cr 10Cr 439.82Cr EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day-1.05%
Current month-1.05%
3 months-1.50%
Current year-14.90%
1 month 85.1
Extreme 85.1
86.4
Current year 81
Extreme 81
86.4
1 year 81
Extreme 81
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 08/04/2013
Director TitleAgeSince
Chairman 54 31/01/2014
Director/Board Member 68 20/06/2013
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.05%0.00%+5.06%+107.56% 4.59Cr
-0.32%-5.97%+57.78%+74.48% 7.04TCr
+3.17%-11.73%+7.71%+57.49% 5.03TCr
+3.20%+1.52%+11.96%+37.53% 4.75TCr
+1.71%+3.16%+30.04%+33.82% 4.29TCr
+2.20%-3.57%+307.79%+467.70% 4.04TCr
+0.49%-3.55%+9.39%+101.85% 3.97TCr
-0.39%-1.48%+10.41%+43.19% 3.06TCr
-2.95%-12.28%+43.51%+1.51% 2.68TCr
+0.33%-5.92%-12.67%-7.59% 2.24TCr
Average +0.65%-5.07%+47.10%+91.75% 3.71TCr
Weighted average by Cap. +1.04%-5.61%+54.77%+95.68%

Financials

2023 2024
Net sales 8.69Cr 91.29L 81.55L 76.01L 68.91L 1.3Cr 87Cr 1.31Cr 9.11Cr 3.56Cr 45Cr 3.43Cr 3.35Cr 144.62Cr 37Cr 3.91Cr 3.49Cr 3.25Cr 2.95Cr 5.55Cr 370.72Cr 5.59Cr 39Cr 15Cr 192.8Cr 15Cr 14Cr 618.68Cr
Net income 3.12Cr 32.74L 29.25L 27.26L 24.71L 46.51L 31Cr 46.88L 3.27Cr 1.28Cr 16Cr 1.23Cr 1.2Cr 52Cr 13Cr 1.32Cr 1.18Cr 1.1Cr 99.85L 1.88Cr 125.56Cr 1.89Cr 13Cr 5.17Cr 65Cr 4.97Cr 4.86Cr 209.55Cr
Net Debt -31Cr -3.27Cr -2.92Cr -2.72Cr -2.47Cr -4.64Cr -310.29Cr -4.68Cr -33Cr -13Cr -161.37Cr -12Cr -12Cr -517.84Cr -25Cr -2.61Cr -2.33Cr -2.18Cr -1.97Cr -3.71Cr -248.06Cr -3.74Cr -26Cr -10Cr -129.01Cr -9.81Cr -9.6Cr -413.98Cr
Projected Income Statement - Annual - Norda ASA
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
  1. Stock Market
  2. Stocks
  3. NORD Stock